ReviewJournal of neural transmission (Vienna, Austria : 1996)2011
Chromogranin peptides in brain diseases.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases.Acta neuropathologica communications · 2014Pooled it
- Molecular requirements of chromogranin B for the long-sought anion shunter of regulated secretion.International journal of biological macromolecules · 2025Article
- Brain Hydrophobic Peptides Antagonists of Neurotoxic Amyloid β Peptide Monomers/Oligomers-Protein Interactions.International journal of molecular sciences · 2023Review
- Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson's Disease.Life (Basel, Switzerland) · 2022Article
- Alterations in blood proteins in the prodromal stage of bipolar II disorders.Scientific reports · 2022Article
- The Interplay Between Brain Vascular Calcification and Microglia.Frontiers in aging neuroscience · 2022Review
- A novel structure associated with aging is augmented in the DPP6-KO mouse brain.Acta neuropathologica communications · 2020Article
- BAMBI and CHGA in Prion Diseases: Neuropathological Assessment and Potential Role as Disease Biomarkers.Biomolecules · 2020Article
- A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.Clinical proteomics · 2020Review
- Article
- Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.Alzheimer's research & therapy · 2018Article
- Amyloid-β Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission.Frontiers in molecular neuroscience · 2017Article
- Neuroanatomical Correlates of Recognizing Face Expressions in Mild Stages of Alzheimer's Disease.PloS one · 2015Article
- Article
- Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study.Journal of neural transmission (Vienna, Austria : 1996) · 2013Article
- CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders.Translational psychiatry · 2013Article
- Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid β-associated neural degeneration in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2013Article
- Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking.Developmental neurobiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synaptic disturbances may play a key role in the pathophysiology of neuropsychiatric diseases. In this article, we review immunohistological findings of chromogranin peptides in neurodegenerative and neurodevelopmental disorders, with particular emphasis on Alzheimer's disease, the disorder chromogranins have been studied most extensively. Data was collected from existing and new experimental data and medline research. This review focuses on synaptic changes elicited by chromogranin peptides immunoreactivity in Alzheimer's disease, as well in schizophrenia and amyotrophic lateral sclerosis (ALS). An imbalanced availability of chromogranin peptides may be responsible for impaired neurotransmission and a reduced functioning of dense core vesicles. Since chromogranin A was postulated as a potent proinflammatory agent, we focused on chromogranin A in neuroinflammation in Alzheimer's disease and ALS. Further understanding of role and function of chromogranin peptides in neuropathological conditions is still required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.